Andy Schwab is a Founder and Managing Partner of 5AM Ventures. Prior to founding 5AM in 2002, Mr. Schwab was a Principal at Bay City Capital where he was involved with companies such as Cubist, PTC Therapeutics and Syrrx. Previously Mr. Schwab was Vice President of Business Development at Digital Gene Technologies and a Vice President in the life science investment banking group of Montgomery Securities. At 5AM, he has led the firm’s investments in and served on the Boards of Bird Rock Bio, Blue Light Therapeutics, Camp4 Therapeutics, Cleave Therapeutics, DVS (acquired by Fluidigm), Enliven, Escient Pharmaceuticals, Flexion Therapeutics (NASDAQ: FLXN), Ikaria (acquired by Mallinckrodt and spun-out), Ilypsa (acquired by Amgen), Novome, Pear Therapeutics (NASDAQ: PEAR), Precision NanoSystems (acquired by Danaher), Purigen and TMRW. Mr. Schwab also serves on the Boards of Trustees of the California Academy of Sciences and Davidson College. He received a B.S. with Honors in Genetics & Ethics from Davidson College and was a member of its 1992 Final Four soccer team. Mr. Schwab is based in the San Francisco, CA office.